Jane O'Donnell

Has grant

Senior Research Fellow

University of Auckland
Country flagNew Zealand

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Health Research Council NZ Grant : Delivery of Respiratory Support in the ED

Open Date: 2023-01-01

Close Date: 2023-01-01

Grant: Close

Fisher & Paykel Hlth Care Ltd Unrestricted Grant: Respiratory Support in ED

Open Date: 2020-01-01

Close Date: 2023-01-01

Grant: Close

Ako Aotearoa Grant : Post Graduate Study Grant - Design and evaluation of a new web-based educational tool for systematic review authoring skills

Open Date: 2011-01-01

Close Date: 2011-12-01

Grant: Close

Smith & Nephew Grant: Post Graduate Study Grant

Open Date: 2010-01-01

Close Date: 2010-01-01

Articles (8)

Year:

2026

Year:

2026

Year:

2025

Background An estimated 20% of emergency department (ED) patients require respiratory support (RS). Evidence suggests that nasal high flow (NHF) reduces RS need. Aims This review compared NHF to conventional oxygen therapy (COT) or noninvasive ventilation (NIV) in adult ED patients. Method The systematic review (SR) and meta‐analysis (MA) methods reflect the Cochrane Collaboration methodology. Six databases were searched for randomized controlled trials (RCTs) comparing NHF to COT or NIV use in the ED. Three summary estimates were reported: (1) need to escalate care, (2) mortality, and (3) adverse events (AEs). Results This SR and MA included 18 RCTs ( n = 1874 participants). Two of the five MA conclusions were statistically significant. Compared with COT, NHF reduced the risk of escalation by 45% (RR 0.55; 95% CI [0.33, 0.92], p = .02, NNT = 32); however, no statistically significant differences in risk of mortality (RR 1.02; 95% CI [0.68, 1.54]; p = .91) and AE (RR 0.98; 95% CI [0.61, 1.59]; p = .94) outcomes were found. Compared with NIV, NHF increased the risk of escalation by 60% (RR 1.60; 95% CI [1.10, 2.33]; p = .01); mortality risk was not statistically significant (RR 1.23, 95% CI [0.78, 1.95]; p = .37). Linking Evidence to Action Evidence‐based decision‐making regarding RS in the ED is challenging. ED clinicians have at times had to rely on non‐ED evidence to support their practice. Compared with COT, NHF was seen to be superior and reduced the risk of escalation. Conversely, for this same outcome, NIV was superior to NHF. However, substantial clinical heterogeneity was seen in the NIV delivered. Research considering NHF versus NIV is needed. COVID‐19 has exposed the research gaps and slowed the progress of ED research.

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Collaborators (6)

Q. Sue Huang

Institute of Environmental Sciences and Research

NEW ZEALAND
View details

Jane Key

Senior Lecturer

Massey University - Albany Campus

NEW ZEALAND
View details

Nikki Turner

Professor

University of Auckland

NEW ZEALAND
View details

Peter McIntyre

Professor

University of Otago

NEW ZEALAND
View details

Janine Paynter

University of Auckland

NEW ZEALAND
View details

Elissa McDonald

-

NEW ZEALAND
View details